BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-02-15 16:00 |
BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combinat…
|
English | 193.5 KB | ||
| 2023-02-15 16:00 |
BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combinat…
|
English | 7.5 KB | ||
| 2023-02-02 06:00 |
BerGenBio Announces the Establishment of Oncology Scientific Advisory Board
|
English | 138.2 KB | ||
| 2023-02-02 06:00 |
BerGenBio Announces the Establishment of Oncology Scientific Advisory Board
|
English | 6.4 KB | ||
| 2023-02-01 06:00 |
BerGenBio ASA: Invitation to fourth quarter 2022 results webcast
|
English | 132.7 KB | ||
| 2023-02-01 06:00 |
BerGenBio ASA: Invitation to fourth quarter 2022 results webcast
|
English | 3.0 KB | ||
| 2022-12-21 07:58 |
Financial calendar
|
English | 682 bytes | ||
| 2022-12-08 06:00 |
BerGenBio to present at DNB's Nordic Healthcare Conference
|
English | 96.2 KB | ||
| 2022-12-08 06:00 |
BerGenBio to present at DNB's Nordic Healthcare Conference
|
English | 2.4 KB | ||
| 2022-11-21 20:30 |
BerGenBio ASA: Grant of share options
|
English | 126.0 KB | ||
| 2022-11-21 20:30 |
BerGenBio ASA: Grant of share options
|
English | 4.1 KB | ||
| 2022-11-15 06:00 |
BerGenBio reports third quarter 2022 financial results and provides business up…
|
English | 6.5 MB | ||
| 2022-11-15 06:00 |
BerGenBio reports third quarter 2022 financial results and provides business up…
|
English | 9.2 KB | ||
| 2022-11-08 06:00 |
BerGenBio ASA: Invitation to third quarter 2022 results webcast
|
English | 131.4 KB | ||
| 2022-11-08 06:00 |
BerGenBio ASA: Invitation to third quarter 2022 results webcast
|
English | 2.9 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
